Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
23.7
USD
|
+0.72%
|
|
+5.24%
|
-1.21%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,354
|
6,227
|
5,784
|
5,174
|
7,460
|
6,987
|
-
|
-
|
Enterprise Value (EV)
1 |
4,502
|
5,020
|
4,317
|
3,865
|
6,465
|
5,876
|
5,335
|
4,666
|
P/E ratio
|
17.3
x
|
57.3
x
|
25.4
x
|
28.6
x
|
36.9
x
|
19.2
x
|
16
x
|
11.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.53
x
|
6.31
x
|
4.03
x
|
3.21
x
|
4.08
x
|
3.66
x
|
3.36
x
|
3.01
x
|
EV / Revenue
|
4.65
x
|
5.08
x
|
3.01
x
|
2.4
x
|
3.53
x
|
3.08
x
|
2.57
x
|
2.01
x
|
EV / EBITDA
|
11.9
x
|
42.1
x
|
14.4
x
|
17.4
x
|
32.9
x
|
12.3
x
|
9.4
x
|
6.61
x
|
EV / FCF
|
8.76
x
|
28.1
x
|
12.8
x
|
17.2
x
|
22.1
x
|
15.8
x
|
11.1
x
|
8.47
x
|
FCF Yield
|
11.4%
|
3.56%
|
7.8%
|
5.8%
|
4.53%
|
6.35%
|
8.99%
|
11.8%
|
Price to Book
|
3.19
x
|
3.4
x
|
2.64
x
|
2.09
x
|
3.21
x
|
2.81
x
|
2.24
x
|
1.83
x
|
Nbr of stocks (in thousands)
|
3,03,846
|
3,10,244
|
3,16,397
|
3,22,561
|
3,10,974
|
2,94,800
|
-
|
-
|
Reference price
2 |
17.62
|
20.07
|
18.28
|
16.04
|
23.99
|
23.70
|
23.70
|
23.70
|
Announcement Date
|
25/02/20
|
10/02/21
|
17/02/22
|
07/02/23
|
06/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
967.8
|
987.5
|
1,435
|
1,611
|
1,830
|
1,911
|
2,078
|
2,323
|
EBITDA
1 |
377.8
|
119.2
|
300.3
|
222.4
|
196.6
|
478.3
|
567.4
|
705.9
|
EBIT
1 |
369.5
|
110.1
|
286.7
|
201.5
|
170.9
|
406.1
|
490.5
|
669.9
|
Operating Margin
|
38.18%
|
11.14%
|
19.98%
|
12.51%
|
9.34%
|
21.25%
|
23.61%
|
28.84%
|
Earnings before Tax (EBT)
1 |
398.1
|
130.8
|
294.2
|
234.4
|
257.5
|
481.4
|
588.3
|
781.8
|
Net income
1 |
321
|
111.8
|
231.1
|
182.3
|
207.8
|
375.5
|
445.6
|
598.7
|
Net margin
|
33.17%
|
11.32%
|
16.1%
|
11.31%
|
11.35%
|
19.65%
|
21.44%
|
25.77%
|
EPS
2 |
1.020
|
0.3500
|
0.7200
|
0.5600
|
0.6500
|
1.236
|
1.477
|
2.005
|
Free Cash Flow
1 |
514.1
|
178.6
|
336.6
|
224.2
|
292.9
|
373
|
479.8
|
551
|
FCF margin
|
53.12%
|
18.09%
|
23.46%
|
13.91%
|
16%
|
19.52%
|
23.09%
|
23.72%
|
FCF Conversion (EBITDA)
|
136.08%
|
149.86%
|
112.08%
|
100.81%
|
148.96%
|
77.98%
|
84.56%
|
78.06%
|
FCF Conversion (Net income)
|
160.16%
|
159.81%
|
145.67%
|
122.97%
|
140.95%
|
99.34%
|
107.67%
|
92.04%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/02/20
|
10/02/21
|
17/02/22
|
07/02/23
|
06/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
328.4
|
451.1
|
356
|
419.4
|
411.7
|
423.9
|
408.8
|
469.8
|
471.9
|
479.7
|
460.5
|
481.3
|
488
|
477.6
|
459.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
88.28
|
-42.13
|
-
|
-
|
-
|
88.31
|
135.6
|
131.8
|
31.71
|
120.1
|
-
|
EBIT
1 |
51.62
|
116.6
|
83.24
|
83.71
|
82.61
|
-48.08
|
28.83
|
77.85
|
-17.58
|
81.79
|
79.5
|
101.9
|
93.64
|
136.3
|
96.46
|
Operating Margin
|
15.72%
|
25.86%
|
23.38%
|
19.96%
|
20.06%
|
-11.34%
|
7.05%
|
16.57%
|
-3.73%
|
17.05%
|
17.27%
|
21.18%
|
19.19%
|
28.53%
|
21.01%
|
Earnings before Tax (EBT)
1 |
53.26
|
118
|
85.23
|
88.51
|
92.04
|
-31.43
|
48.28
|
100.4
|
5.818
|
103
|
101.1
|
124
|
111.6
|
140.3
|
113.7
|
Net income
1 |
38.2
|
95.17
|
68.57
|
70.67
|
73.21
|
-30.17
|
40.03
|
81.18
|
1.041
|
85.52
|
81.11
|
97.32
|
90.09
|
105.7
|
89.8
|
Net margin
|
11.63%
|
21.09%
|
19.26%
|
16.85%
|
17.78%
|
-7.12%
|
9.79%
|
17.28%
|
0.22%
|
17.83%
|
17.61%
|
20.22%
|
18.46%
|
22.14%
|
19.56%
|
EPS
2 |
0.1200
|
0.2900
|
0.2100
|
0.2200
|
0.2300
|
-0.0900
|
0.1200
|
0.2500
|
-
|
0.2700
|
0.2382
|
0.3099
|
0.3017
|
0.3891
|
0.3450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/11/21
|
17/02/22
|
10/05/22
|
09/08/22
|
01/11/22
|
07/02/23
|
09/05/23
|
01/08/23
|
01/11/23
|
06/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
852
|
1,207
|
1,467
|
1,308
|
995
|
1,111
|
1,652
|
2,321
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
514
|
179
|
337
|
224
|
293
|
373
|
480
|
551
|
ROE (net income / shareholders' equity)
|
21.6%
|
10.8%
|
11.3%
|
7.76%
|
8.74%
|
15.5%
|
16.4%
|
16.8%
|
ROA (Net income/ Total Assets)
|
19.4%
|
-
|
9.72%
|
6.41%
|
6.91%
|
11.2%
|
11%
|
12.6%
|
Assets
1 |
1,654
|
-
|
2,377
|
2,844
|
3,007
|
3,352
|
4,051
|
4,752
|
Book Value Per Share
2 |
5.530
|
5.910
|
6.930
|
7.680
|
7.480
|
8.420
|
10.60
|
12.90
|
Cash Flow per Share
2 |
1.670
|
0.6600
|
1.240
|
1.120
|
1.040
|
1.330
|
1.730
|
2.300
|
Capex
1 |
12.8
|
30.3
|
64.2
|
138
|
40.5
|
35.2
|
33.7
|
34.9
|
Capex / Sales
|
1.33%
|
3.07%
|
4.48%
|
8.59%
|
2.21%
|
1.84%
|
1.62%
|
1.5%
|
Announcement Date
|
25/02/20
|
10/02/21
|
17/02/22
|
07/02/23
|
06/02/24
|
-
|
-
|
-
|
Last Close Price
23.7
USD Average target price
26.63
USD Spread / Average Target +12.38% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.21% | 6.99B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|